Antibody evasion properties of SARS-CoV-2 Omicron sublineages


The identification of the Omicron variant (B.1.1.529.1 or BA.1) of SARS-CoV-2 (extreme acute respiratory syndrome coronavirus 2) in Botswana in November 20211 instantly raised alarms as a result of sheer variety of mutations within the spike glycoprotein that would result in hanging antibody evasion. We2 and others3-6 just lately reported outcomes on this Journal confirming such a priority. Persevering with surveillance of Omicron evolution has since revealed the rise in prevalence of two sublineages, BA.1 with an R346K mutation (BA.1+R346K, often known as BA.1.1) and B.1.1.529.2 (BA.2), with the latter containing 8 distinctive spike mutations whereas missing 13 spike mutations present in BA.1. We subsequently prolonged our research to incorporate antigenic characterization of those new sublineages. Polyclonal sera from sufferers contaminated by wild-type SARS-CoV-2 or recipients of present mRNA vaccines confirmed a considerable loss in neutralizing exercise in opposition to each BA.1+R346K and BA.2, with drops akin to that already reported for BA.12,3,5,6. These findings point out that these three sublineages of Omicron are antigenically equidistant from the wild-type SARS-CoV-2 and thus equally threaten the efficacies of present vaccines. BA.2 additionally exhibited marked resistance to 17 of 19 neutralizing monoclonal antibodies examined, together with S309 (sotrovimab)7, which had retained considerable exercise in opposition to BA.1 and BA.1+R346K2-4,6. This new discovering exhibits that no licensed monoclonal antibody remedy might adequately cowl all sublineages of the Omicron variant, aside from the just lately licensed LY-CoV1404 (bebtelovimab).

Leave a Reply

Your email address will not be published. Required fields are marked *